# GAVI SUPPORT FOR YELLOW FEVER DIAGNOSTIC CAPACITY

BOARD MEETING **Hope Johnson, PhD**28-29 November 2018, Geneva



### Gavi and Yellow Fever (YF)

#### Yellow fever outbreaks are a major problem

- Since 2015: Angola, Brazil, DRC, Ethiopia, Nigeria, Republic of Congo and Uganda
- Much of Africa is now at high risk for yellow fever


## Gavi has approved up to US\$ 428 million for yellow fever vaccine use during 2016-2020

- Severe disease without a specific treatment or cure
- Vaccination is the main form of prevention

#### YF vaccine supply remains limited


## Reliable YF diagnostic capacity can improve the impact and efficiency of Gavi's investment

• Early and specific detection, targeting vaccination






# Timely Detection and Response Prevents Further Death and Disease – Case of Angola YF Outbreak



Source: Zhao et al, Modeling the Large-scale Yellow Fever Outbreak in Luanda, Angola, and the Impact of Vaccination, PLOS Neg Trop Dis, 2018, 12:e0006158.



# Long Timelines to Laboratory Confirm Yellow Fever Highlights Areas for Improvement



Board meeting 28-29 November 2018

# Gavi Alliance Assessments and Stakeholder Outreach Have Identified Laboratory Capacity Gaps

#### **Data Source**

- Yellow fever diagnostic market assessment
- Yellow fever laboratory capacity assessments
- Eliminating Yellow Fever Epidemics Laboratory Technical Working Group
- Laboratory capacity assessment
- Donor outreach

#### Gaps



- Validated, standardized yellow fever tests not available




- Frequent supply stockouts
- Insufficient yellow fever training
- Limited Quality Assurance/Quality
   Control (QA/QC) testing
- Sample transportation bottleneck



- Lack of funding for yellow fever testing supplies and equipment



### Estimated Need for US\$ 13.5 million for 2019-2021



Applies to 26 African countries eligible for Gavi support at high risk for YF Countries can continue to use HSS, other funds for general lab infrastructure



### Recommendation (1/2)

The Gavi Alliance Programme and Policy Committee recommends to the Gavi Alliance Board that it:

**Approve**, an amount of up to US\$ 8.2 million during 2019-2021 (of which US\$ 4.6 million would be for 2019-2020) for costs related to the procurement and distribution of laboratory reagents, supplies, and equipment for yellow fever diagnostic capacity strengthening through a diagnostic procurement mechanism based on Gavi's existing application, review, and approval processes;



### Recommendation (2/2)

- b) <u>Note</u> the expected use of PEF funds, estimated at approximately US\$ 5.3 million during 2019-2021, to support yellow fever diagnostic capacity strengthening; including technical assistance, quality assurance/quality control assessments, support for sample transportation, and coordination. The Gavi Secretariat will seek to absorb the 2019 estimated costs of US\$1.7 million within existing approved budgets;
- c) <u>Note</u> the continued limited use of HSS funds to support surveillance and laboratory capacity in the context of national plans that focus on achieving and maintaining high immunization coverage and address underlying equity challenges; and
- d) Request the Gavi secretariat to report back to the PPC and Board on progress in 2019.



